

TABLE OF CONTENTS

June 18, 2007

No. 2045

BUSINESS

- 1 Takeda Looks for Alliance, Acquisition Opportunities: President Hasegawa
 - Mr Tsuji Calls For National Consensus to Use Medical Fees for Clinical Research
 - New NHI Pricing System that Encourages R&D Is Needed: Mr Hosoda
 - Eight-item Declaration Adopted
- 3 Sales of 23 TSE Section 1 Companies Up 2.2%
- 4 Bulk Buying by Sum Value Should Be Eliminated: FJPWA President
- 6 OPIR Proposes Actual Purchase Price Reimbursement System
- 6 Market for Ethical Drugs Declined 0.5% in FY2006: IMS
 - Takeda Stays No. 1 Both as Distributor, Promotion Company
 - Sales of Ethical Drugs Up 0.8% in 1st QTR 2007
- 6 Nikko, Daiwa Downgrade Chugai's Share due to Avastin's Lower-Than-Expected NHI Prices
 - Unpleasant Surprise
 - Switch from Epogin to Nesp Will Be Extensive: Nikko
 - DIR Reduces Sales Forecast for Avastin by 36%
 - Epogin Will Not Be Quickly Switched to Nesp: DIR
- 8 Annual Pay Raise Averages ¥6,627 for 8 Pharma Companies
- 10 Diovan Recaptures Top Position in April
- 11 **BUSINESS NEWS IN BRIEF**
 - Site Support Institute: Back to the Black with Improved Profitability
 - Irom Suffers from Losses Despite Growth in Sales
 - Irom Pharm. Jointly Develops Generic Injectable Granisetron
 - SNBL: US Business Props Up Sales and Profits

GENERIC

- 12 Mr Sawai Responds to His Criticisms
- 12 **GENERIC NEWS IN BRIEF**
 - Nichi-Iko to Withdraw from OTC Drug Business
 - Maruko Reports First Profits Since Acquisition by Nichi-Iko
 - Transfer of Prescriptions by Fax Interferes with Use of Generics: Mr Mitsuhashi
 - GL on Bioequivalency Tests for Generics Revised
 - Generics Viewed as Less Reliable: Intage Survey

REGULATORY

- 14 28 Drugs (13 APIs) Included in NHI Price List
 - 341 Full-Timers in April
- 14 77 Applications for New Drugs Approved in FY2006: PMDA
 - Review Timeclock to Be Shortened by 1 Year by FY2011
 - Safety Measures to Be Top Priority in 2nd Mid-Term Plan
- 15 Reconsider Insurance Coverage of Long-listed

Original Drugs, OTC Drug-Like Ethical Drugs: Council

- Long-Listed Original Drugs Are Major Source of Savings

16 REGULATORY NEWS IN BRIEF

- TORISEL Approved for RCC in the US: Wyeth

- Taxotere to Receive Priority Review for Prostate Cancer

- PI Trial of SGLT-2 Inhibitor Underway by J&J: Tanabe

- JPA Opposed to More Frequent NHI Price Revisions: Mr Yamamoto

R&D

17 R&D NEWS IN BRIEF

- BioMedCore to Develop Anticancer Drugs Using New DDS

- LTT Bio-Pharma Receives Data on PC-SOD from Seikagaku

- Long-Term Data Shows Efficacy of CIMZIA for Crohn's Disease: UCB

- Dipyridamole + Aspirin Combination Prevents Recurrent Stroke: BI

MEDICAL DEVICES

18 Five Medical Devices Recommended for Priority Review

18 MEDICAL DEVICE NEWS IN BRIEF

- Eiken to Supply Its Products to bioMérieux Japan's Customers

- AMO Japan Voluntarily Recalls Contact Lens Solution

- *Koroshio* to Set Requirements for High-Risk Medical Devices

SELF-MEDICATION

19 40,000-50,000 Registered Drug Salespersons Needed at First: JACDS SG

19 Consensus Not Reached on the Need for Practical Experience: Exam for Drug Salespersons

19 Mr Matsumoto Reelected JACDS President

20 Taisho to Start Ads Using Clinical Data

MEDICAL FACILITIES & NURSING CARE

20 Janssen to Bear Costs of Velcade in Non-Responsive Patients: UK Guidance

20 Acute Stage Rehabilitation Important: *Koroshio*

21 Arixtra Should Promote Awareness of VTE: GSK

21 JPA Concerned about Excess of Pharmacists

- 10,000 New Pharmacists per Year

22 WG Inaugurated to Predict Demand & Supply for Pharmacists

- Drug Firms Should Hire More Pharmacists: Universities

22 Survey

- Metabolic Syndrome Affects 19 Mil. Japanese

- 60% of Cerebral Infarction Patients Unaware of Recurrence Risk

- COPD Suspected in 20% of Asymptomatic People: NBI, Pfizer